About
Exosome-delivered CD24-based Therapeutics
OBCTCD24 is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-delivered, CD24-based therapeutics a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.
Identity
| Name | OBCTCD24 |
|---|---|
| Slug | obctcd24 |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Of0zvkLDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Dec 2021 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Tel Aviv, Israel |
Web & social
| https://www.linkedin.com/company/70961582 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcareProviders
Business models
B2B
Tags
autoimmune-diseasespharmaceuticalshealthcare-providersdrug-developmentbiopharmaceuticalrespiratorytherapeuticsbiotechnologyinhalation
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}